Current Full CV and research interest

1. Curriculam Vitae
******
Dr. SURENDRA PAL CHAUDHARY
PERSONAL DETAILS
Name : Dr. Surendra Pal Chaudhary
Date of Birth : February 1st, 1976
Marital Status : Single
Permanent Address : S-2, 132B Greater Green Park,
Bareilly 243001, Uttar Pradesh, India
Present Address : Room No-229, 2nd
floor,
Department of Medical Oncology
DrBRA.Institute Rotary Cancer Hospital
All India Institute of Medical Sciences
New Delhi – 110029.INDIA
Cell:+91-9910366231
Ph. & Fax 91-112-658-9490
E-mail & Skype- drsurendra101@gmail.com
dr_surendra2006@yahoo.co.in
CURRENT DESIGNATION
Senior Research Officer (Medical Oncology)
Department of Medical Oncology
Dr BRA.Institute Rotary Cancer Hospital
All India Institute of Medical Sciences
New Delhi, India
Since: May 2016
AIMS & OBJECTIVES
With my extensive clinical oncology and research experience with huge International
exposure I wish to carry forward Oncology Clinical Research (Phase I-IV) oncology
clinical trials in highly dynamic and challenging research environment with longterm
commitment,where I can showcase my skills and contibute in the advancement of cancer
therapies.
ROLES,RESPONSIBILITIES & SKILLS
Summary:

2. Coordinates or co-leads assigned clinical research projects in accordance to
Protocols, Standard Operating Procedures (SOPs), and applicable regulations.
Essential Functions:
1. Oncology Clinical Research Project Plan and Preparation (Phase I-IV)
a) Review of assigned protocols and other protocol documentation (ICF, IB) for
accuracy, feasibility, timing, and resources.
b) Prepares and maintains the Trial Master File (TMF) for the study.
c) Participates in creation and review of timelines and start-up meetings
(Investigator Meeting/SIV, Sponsor discussions, or other related meetings)
d) Takes the lead and/or overall coordination of all required start-up activities
e)Clinic logistics planning, schedule of clinic activities, and team training
f) Preparation, review, and/or finalization of clinic source documents, time and
events tables, and other required study materials; review of Case Report Forms
(CRFs), laboratory workbooks, staff requirements, and schedules
g)In collaboration with the responsible teams, establishes and/or maintains safety
assessment requirements, Quality Control (QC) and monitoring plans,
pharmacy/dispensing requirements, study supplies
h)Confirms all required regulatory and contractual documentation is present prior
to study start
i)Electronic Data Entry, analysis interpretation
j)Preparation and submission of Abstract and manuscript
k)Well trained with ICH-GCP Guidelines ,FDA 1572 Financial Disclosure form
2. Clinical Conduct
a) Coordinates and monitors screening activities; provides support as required
b) Coordinates and ensures set-up of clinic rooms, subject chart review, and source
preparation prior to start of clinic activities
c) Takes the lead and/or overall coordination of clinic activities
e)Supervises clinic visits (admission, dosing and randomization, discharge, and
follow-up) as required and provides on-call support when applicable
f)Ensures volunteer eligibility prior to randomization; oversees or performs drug
administration, and other activities as delegated and required
g)In collaboration with the responsible teams, monitors that all study-related
activities are conducted according to protocol, SOP, and applicable regulations
d) Reviews and manages clinic updates, Adverse Event (AE) or Serious Adverse
Events (SAEs) reporting, study logs and tracker, quality control, and Monitor
findings
e)Blood sampling and other investigation in accordance with the Study Protocol
f)Supervising and guiding medical students, fellows and PhDs in their thesis and
dissertations
g)New cancer patients work up, examination, evaluation for chemotherapy and

3. planning of all hematological and solid tumors
h)Toxicity assessment and management
i)Tumor response evaluation (RECIST)
j)Clinical Grand Rounds and Tumor boards on Head and Neck and Gastric and
Colorectal Cancer
k)Assessing and Screening the suitable patients for enrolling in ongoing clinical
trials
3. Post-Clinic/Close-Out Activities
a) Coordinates resolution and/or address QC, monitor, CRF, or other
internal/external findings
b) Reviews and/or oversees close-out of study documentation, deviation reporting,
CRF completion and sign-off, and other study-related reports/documentation
c) Reviews and updates TMF documentation
d) Finalizes study and/or volunteer logs
e) Ensures completion of other close-out activities as required (return of study
supplies, IRB reports, archiving, etc.)
4. Responsible for monitoring subjects’ compliance throughout the trial and
address day-to-day subject or study issues and escalate as appropriate.
5. Prepares for and participates in sponsor/monitor/QA audits.
6. Provides accurate and timely project status updates to Ethics Committee and
Sponsors
7. Collaborates within and between teams during process improvement exercises,
SOP creation and/or revision, internal and external meetings, and other company-
related initiatives and goals.
8. Arrange flexible schedule for Clinical Trial Patients
9.Study Close outs and documents archival in accordance with Protocol
EDUCATIONAL QUALIFICATION
M.B.B.S.(Bachelors of Medicine and Bachelors of Surgery)
Lala Lajpat Rai Memorial Medical College associated with Chaudhary Charan Singh
University ,Meerut,Uttar Pradesh,INDIA.
MEDICAL LICENSURE
State Medical Council,Lucknow, Uttar Pradesh, India
Registration #046296 (dated 26 April 2002)

4. INTERNSHIP TRAINING
Duration: 1st
April 2001-31 March 2002
Institution and Hospital: Lala Lajpat Rai Memorial Medical College and associated
Sardar Vallabh Bhai Patel Hospital
Meerut, Uttar Pradesh, India
POST GRADUATE TRAINING
• Junior Resident in Department of Orthopedic surgery at Lady Hardinge Medical
College, New Delhi, India (September 2005- December 2005)
• Junior Resident in Department of Accident and Emergency Medicine at Ram
Manohar Lohia Hospital, New Delhi, India (November 2004-August 2005)
• Junior Resident in Department of Dermatology at Ram Manohar Lohia Hospital, New
Delhi, India (May 2004-November 2004)
• Junior Resident in Department of Pediatrics, University College of Medical Sciences
& G.T.B. Hospital, New Delhi, India (October 2003-March 2004)
• Junior Resident in Department of Anesthesia and critical care at University College
of Medical Sciences and & G.T.B. Hospital, New Delhi. India (April 2003-September
2003)
RESEARCH EXPERIENCE
• A Randomized Double Blind Placebo Controlled Phase III Study of Efficacy of
Lactobacillus CD2 lozenges in Preventing High-Dose Chemotherapy Induced Oral
Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell
Transplantation.(March 2013-Current)-Sponsored by CD Pharma India Pvt ltd
• Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers, An International Multi-
centre, Double Blind, Randomized Placebo Controlled phase III Trial
(ICRO2/ASCOLT).(April 2012-Present)-Sponsored by Singapore Clinical Research
Institute, Singapore
• INDOX cancer Research Network, Oxford University,UK(Sept 2012-Dec2015)

5. • A pilot study of efficacy of Lactobacillus CD2 lozenges in preventing high-dose
chemotherapy induced oral mucositis in patients undergoing hematopoietic stem cell
transplantation.(December 2011-December 2012)-Sponsored by CD Pharma India Pvt
Ltd
• A Randomized controlled trial comparing modified Gemcitabine+Oxaliplatin
(mGEMOX) to Gemcitabine+Cisplatin in management of unresectable gall bladder
cancer.(January 2011-January 2016)-Investigator initiated Trial,AIIMS,New Delhi
• A multicenter,pilot phase II trial assessing the efficacy and safety of
Bevacizumab+gemcitabine+Carboplatin as first line treatment for diagnosed with Triple
negative Breast Cancer.(2011-2016)-Sponsored Roche India
• Concomitant chemo radiation using weekly cisplatin for advanced squamous cell
carcinoma of head and neck”: Experience from tertiary cancer center in India (2011)-
Investigator initiated AIIMS,New Delhi
• Phase II/III, randomized, double-blind, placebo controlled study to investigate the
efficacy of a probiotic VSL#3®
, on Chemotherapy-induced diarrhea in cancer patients
receiving Fluropyrimidines and or Irinotecan (2010-Present)-Sponsored by CD Pharma
India Pvt Ltd
• “An Asia pacific non randomized ,open–label phase II study evaluating the safety and
efficacy of FOLFIRI plus cetuximab (Erbitux) or FOLFOX plus cetuximab in subject
with KRAS wild type metastatic colorectal cancer (APEC study) (2009-Present)-
Sponsored by Merk Sereno India
• A phase III study of Erb B2 positive advanced or metastatic gastric/ gastric/
esophageal/gastro-esophageal junction adenocarcinoma treated with capecitabine
+oxaliplatin with/without lapatinib (LOGIC Trial) (2009-2014)-Sponsored by GSK India
• A randomized,open label ,Two arm study of Neratinib plus Paclitaxel vs Trastuzumab
plus Paclitaxel as First line treatment for Erb-B2 possitive locally recurrent or metastatic
Breast Cancer.(2009-current)-Sponsored by Roche India
• A Phase III,open label,randomized multicenter trail of Ofatumumab+chlormabucil
combination Vs chlorambucil monotherapy in previously untreated patient with CLL
(2009-current)-Sponsored by GSK India

6. • A Phase III,open label,randomized trial of Ofatumumab added to
Fludrabine+Cyclophosphamide combination Vs Fludrabine Cyclophophamide
combination in subject with relepse CLL (2009)-current)-Sponsored by GSK India
• A randomized, phase IIIb, multicentric open parallel study of Enoxaprin (low molecular
weight heparin) given concomitantly with chemotherapy versus chemotherapy alone in
patients with inoperable gastric and gastro-esophageal cancer (2008-2012)-Sponsored by
Thrombosis Research Institute, UK
• A phase II, Multicentric, open label. randomized study of Mapatumumab (TRM-1[HGS
1012], a fully human monoclonal antibody to TRAIL-R1) in combination with
bortezomib (VELCADE) and bortezomib alone in subjects with relapsed or refractory
Multiple Myeloma (2007-2009)-Sponsored by Human Genome Sciences ,USA
• A randomized Multicentric therapeutic phase II study to evaluate the efficacy and
safety of Proxinium plus best supportive care versus best supportive care alone in patient
with advance squamous cell carcinoma of head and neck who has received at least one
anti cancer treatment regimen for advanced disease (2007-2008)-Sponsored by Viventia
Biotech,Canada
• A randomized double blind phase III study of the efficacy of lactobacillus brevis
lozenges in preventing radiation and chemotherapy induce oral mucositis in head and
neck cancer (2007-2009)-Sponsored by CD Pharma India Pvt Ltd
• Best Supportive care compared with chemotherapy for uresectable gall bladder cancer: A
randomized controlled study (2006-2009)-Investigator Initiated Trial,AIIMS,New Delhi
• A phase III, Multicentric, Randomized, Double -blind ,Active Controlled, Parallel Group
Study of the Safety and Efficacy of the Intravenous and Oral Formulation of the
Neurokinin-1 Receptor Antagonist ,Casopitant (GW679769) in combination with
Odenseteron and Dexamethasone for the prevention of nausea and vomiting induced by
moderately emetogenic chemotherapy (2006-2007)-Sponsored by GSK India
• A Multicentric, open label, randomized phase III trial comparing immediate adjuvant
hormonal therapy (Eligard-leuprolide acetate) in combination with Taxotere (Docetaxal)
administered every three weeks versus hormonal therapy alone versus deferred therapy
followed by the same therapeutic options in patient with prostate cancer at high risk of
relepse after radical prostactomy (2006-2007)-Sponsored by Sanofi India

7. • A Multicentric open label ,comparative randomized (phase IV) study to optimize the
dose, duration, safety and efficacy and cost of two treatment regimen with liposomal
ampotericin –B (fungisome) in the treatment of systemic fungal infection in INDIA
(2006-2007)-Sponsored by King Edward Medical College,India
• A randomized phase III trial of the efficacy and safety of Glufosfamide compared with
the best supportive care in metastatic pancreatic adenocarcinoma previously treated with
Gemcitabine (2006-2007)-Sponsored by Threshold Pharmaceutical,USA
INTERNATIONAL CONFERENCES & INVESTIGATOR MEETINGS
• ESMO Preceptorship meeting on Prostate Cancer 23-24 June 2016,Prague ,Czech
Republic
• ESMO Preceptorship meeting on NSCLC 15-16 Decemeber 2015,Singapore
• ESMO Preceptorship meeting on Immunotherapy in Cancer,4-5 Decemeber
2015,Lund,Sweden.
• ESMO Preceptorship meeting on Immuno-Oncology 20-21 November
2015,Zurich,Switzerland
• ESMO Symposium on Immunoloncology 18-19 November 2015,Laussane,Switzerland.
• Clinical Case presentation and Discusion ESMO Preceptorship Meeting on Gastric
Cancer 13-14 Novemeber 2015,Singapore
• Clinical Case presentation and Discusion ESMO Preceptorship Meeting on
Colorectal Cancer 26-27 Ocober 2015,Vienna,Austria
• ESMO Preceptorship on Prostate Cancer 9-10 April 2015 Prague,Chzech Republic
• ESMO Preceptorship Meeting on Colo-rectal Cancer 27 and 28 March 2015,Singapore
• ESMO Sympsium Signalling Pathways in Cancer 13-14 March Barcelona,SPAIN.
• ESMO Preceptorship Meeting on Immunotherapy 23-24 Januaray 2015,Manchester
UK
• ESMO Symposium on Immuno-Oncology,21st
-22nd
Novemeber2014
,Geneva,Switzerland
• European Society of Medical Oncology 26th
-30th
September 2014,Madrid,SPAIN
• Multinational Association of Supportive Cancer Care 2014”A pilot study of efficacy
of lactobacilus CD2 lozenges in preventing high-dose chemotherapy induced oral
mucositis in patients undergoing hematopoietic stem cell transplantation” Multinational

8. Association of Supportive Cancer Care 26-28 June 2014, Miami,Florida,USA.(Final
Analysis) (POSTER PRESENTATION and E-Poster Presentation and Discussions)
(Abstract was also selected for MASCC Travel Scholarship Award 2014)
• American Society of Clinical Oncology(ASCO) annual meeting 2014 as co-author for
the study “A randomized controlled trial comparing modified gemcitabine plus
oxaliplatin (mGEMOX) to gemcitabine plus cisplatin in the management of unresectable
gall bladder cancer.ASCO.Abstract no:TPS 4162.May 30th
May -3rd
June
2014,Chicago ,Illinois,USA.(POSTER PRESENTATION)
• NET Case Presentation and discussion during ESMO Preceptorship Meeting on GI
Neuroedocrine Tumour (NETs) 11-12th
April 2014,Singapore
• ESMO Symposium on Immuno-Oncology,15th
16th
Novemeber2013 ,Geneva,Switzerland
• European Society of Medical Oncology 2013 as presenting author for the study “ A
phase II / III, randomized, double-blind, placebo controlled study to investigate the
efficacy of a probiotic VSL#3®
, on Chemotherapy-induced diarrhoea in cancer patients
receiving fluropyrimidines and or irinotecan (Interim analysis)” Abstract no 1319
ECCO-ESMO-ESTRO 27th
-1st
October 2013,Amsterdam,Netherland.(POSTER
PRESENTATION)
• INDOX Residenatial Training and fellowship on Randomized Clinical trials 16th
September-20th
September 2013,University of Oxford,Oxford,UK.
• American Society of Clinical Oncology(ASCO) annual meeting 2013 as co-author for
the study “A randomized controlled trial comparing modified gemcitabine plus
oxaliplatin (mGEMOX) to gemcitabine plus cisplatin in the management of unresectable
gall bladder cancer.ASCO.Abstract no:TPS 4162.May 31st
-4th
June 2013,Chicago
,Illinois,USA.(POSTER PRESENTATION)
• ESMO Translational Research Unit Visit 2013,15th
-17th
May 2013,Innsbruck,Austria
• European Society of Medical Oncology 2012,28t
Sept -2nd
October 2012,Vienna,Austria.
• ASCO Annual Meeting 2012,1-5 June Chicago,Illinois,USA.
• European Society of Medical Oncology, ECCO 2011, September 2011, Stockholm,
Sweden.
• American Society of Clinical Oncology (ASCO) annual meeting 2011 as co-author for
the study “Concomitant chemo radiation using weekly cisplatin for advanced squamous
cell carcinoma of head and neck”: Experience from tertiary cancer center in India.
(abstract no:5548, (POSTER PRESENTATION) , 3-7 June 2011, Chicago, Illinois,
USA.
• American Society of Clinical Oncology (ASCO) annual meeting-2009 as sub investigator
for the study entitled “A randomized double blind study of the efficacy of Lactobacillus

9. brevis lozenges in preventing radiation and chemotherapy induce oral mucositis in head
and neck cancer” (Abstract no-6008,(ORAL PRESENTATION) at Orlando
FLORIDA, USA (2009)
• LOGIC investigators meet at Mumbai India (April 24th
to 25th
2009)
• APEC Investigators meet at Singapore (December 13th
2008)
• Investigators meet for TRI-0702(Gastronox) study at Mumbai, India (March 1st
2008)
• Viventia Target Investigator meet for Head and Neck cancer at Banglore, India (October
12th
2007)
• Viventia Target Investigator meet for Head and Neck cancer Held at Dubai, UAE (May
20th
to 21st
2007)
• G-CINV Investigators meet for protocol NKV 102549 and NKV 102551 at Bangkok,
Thailand (September 14th
2006)
WORKSHOPS/CMEs/PRESENTATIONS
• Investigator Presentation for the approval of “lactobacillus CD2 lozenges in preventing
radiation- and chemotherapy-induced oral mucositis in Head and Neck cancer
patients,10th
June, New Drug Approval Committee(NDAC)/Drug Control General of
India (DCGI), New Delhi INDIA.
• INNOVATIONS IN ONCOLOGY:Targated Therapies and Cancer Vaccines,New
Delhi,(March 18th
2012)
• CME on (European Society of Medical Oncology) ESMO ASIA CME
PARTNER:Colorectal Cancer Programme, New Delhi India, (February 17th
2012)
• CME on (European Society of Medical Oncology) ESMO Oncology Summit India 2011,
New Delhi, India (April 22nd
2011)
• CME updates on Breast cancer by American School for Continuing Medical Education,
USA (2010)
• International Symposium on Molecular Pathology and Applied genomics at
New Delhi, India (6th
and 7th
November 2009)
• CME Updates on breast cancer, by John Hopkins University School of Medicine, USA
(2009)
• Faculty Research Presentation entitled “A randomized double-blind phase III study of
efficacy of lactobacillus CD2 lozenges in preventing radiation- and chemotherapy-
induced oral mucositis in head and neck cancer patients” at AIIMS, New Delhi,
India (2009)
• Advanced course in Molecular Oncology conducted by Indian Society of Medical and
Pediatric Oncology/ American Society of Clinical Oncology (ASCO) at New Delhi,
India. (13th
May 2007)
• Proxinium Intratumour Injection Training held at Dubai, UAE (May 20th
to 21st
2007)

10. • Remote data capturing training by PPD, during target investigator meet at Dubai, UAE
(May 20th
to 21st
2007)
NATIONAL CONFERENCES, WORKSHOPS AND CMEs
• Symposium on “Lab Technology in Oncology FISH,CYTOGENETICS,
FLOWCYTOMETERY,ELISA and RT-PCR :Basic Principles, Interpretation and
clinical utility” 25th
January and 1st
February 2014,IRCH,AIIMS,New Delhi.
• Symposium on Unresolved Issues in Clinical Oncology at New Delhi (5th
December
2010).
• Certificate course in Essentials of Palliative Care at All India Institute of Medical
sciences, New Delhi, INDIA (1st
August 2009)
• AIIMS Head and Neck CME: Surgical and non Surgical approaches to disability
limitation at the All India Institute of Medical Science, New Delhi (March 15-17 2008)
• CME on Chronic Myeloid Leukemia Organized by Rajeev Gandhi Cancer Institute and
Research Centre, New Delhi in association with the Association of Physicians of India,
Delhi State Chapter at New Delhi (October 7th
2007)
• Conference on “Comprehensive Cancer Care Preventive, Curative and Palliative”
Organized by Institute Rotary Cancer Hospital, AIIMS, New Delhi (November 18th
to 19,
2006)
• Clinical Excellence Programme conducted by Sanofi Aventis at New Delhi, India
(September 8th
2006)
• Leprosy Awareness Programme Technical-Cum-Pod Training organized by Directorate
of Health Services Govt. of NCT at Dr Ram Manohar Lohia Hospital, New Delhi, India
(September 27th
to 29th
2004)
• CME on Pediatric Dermatology Organized by Department of Dermatology and
Venereology at Vardhman Mahavir Medical College and Safdarjung Hospital at New
Delhi, India (September 12th
2004)
• Prof. H.S. Mittal Memorial Foundation 7th
Annual CME Programme at L.L.R.M medical
College, Meerut (UP) India (April 4th
1999)
VOLUNTEER AND COMMUNITY ACTIVITIES
• Coordinating Glivec International Patient Assistance Program (GIPAP) for CML and
GIST patients at AIIMS
• Awareness Campaign for public on Cancer Education and their prevention.
• Participated in Terry Fox Run 2008 at New Delhi, India organized by Indo- Canadian
Cancer Research Foundation (September 14th
2008)

11. • Joined The Glory “send your name around earth” project, By Goddard Space Flight
Center Mission NASA, USA (2009)
• Dissection competition organized by the Department of Anatomy, LLRM Medical
College, Meerut, U.P., India (1997)
• Participated actively in the Pulse Polio Immunization Programs (2001-2002)
EXTRA CARRICULAR ACTIVITIES :
• Painting, draw cartoons and caricature, playing tennis, swimming, photography,
participating and organizing cultural activities and Health Awareness Campaigns.
MEMBERSHIPS :
• American Society of Clinical Oncology (ASCO) ID:90007.
• European Society of Medical Oncology (ESMO) ID:81498
• Multinational Association of Supportive Cancer Care (MASCC):031403
FELLOWSHIPS ,TRAVEL GRANTS ,HONOURS AND AWARDS :
• ESMO Travel Grant for the Preceptorship meeting on Prostate Cancer,23-24 June
2016,Prague,Czech Republic
•
• ESMO Travel Grant for the Preceptorship meeting on NSCLC 15-16 Decemeber
2015,Singapore
• ESMO Travel Grant for the Preceptorship meeting on Immunotherapy in Cancer,4-5
Decemeber 2015,Lund,Sweden.
• ESMO Travel Grant for the Preceptorship meeting on Immuno-Oncology 20-21
November 2015,Zurich,Switzerland
• ESMO Travel Grant for the Symposium on Immunoloncology 18-19 November
2015,Laussane,Switzerland.
• ESMO Travel Grant for the Preceptorship meeting on Gastric Cancer 12-13 November
2015,Singapore
• ESMO Travel Grant for the Preceptorship meeting on Colorectal Cancer 26-27 Ocober
2015,Vienna,Austria
• ESMO Travel Grant for Preceptorship on Prostate Cancer 9-10 April
2015,Prague,Czech Republic
• ESMO Travel Grant for Preceptorship on Colo-rectal Cancer 27-28 March,Singapore

12. • ESMO Travel Grant for Signalling Pathways in Cancer 13-14th March
2015,Barcelona,Spain.
• ESMO Travel Grant for ESMO Preceptorship Meeting on Immunotherapy 23-24
January 2015,Manchaster,UK.
• ESMO Travel Grant to the Symposium on Immuno-Oncology,21st
-
22nd
Novemeber2014 ,Geneva,Switzerland
• MASCC International Travel Scholarship Award for Multinational Association of
Supportive Cancer Care (MASCC) 26th
-28th
June 2014,Miami,Florida,USA
• ESMO Travel Grant for ESMO Preceptorship Meeting on GI Neuroedocrine Tumour
(NETs) 11-12th
April 2014,Singapore
• Biography published in “Marquis Who's Who” in the World 2014 ,2015 (31st
and
32nd Edition)
• ESMO Travel Grant to the ESMO Symposium on Immuno-Oncology,15th
16th
November 2013,Geneva,Switzerland
• Randomized Controlled Trial Certificate Course under INDOX Residential Training
and Fellowship Scheme (16th
September-20th
September 2013) at Pembroke
College ,University of Oxford ,Oxford,UK.
Topic:Randomized Clinical Trials (Design,Conduct,Analysis,Interpretation and
Reporting)
• ESMO Translational Research Unit Visit at Innsbruck Medical University and Center
for Personalized Medicine “Oncotyrol” (15th
-17th
May 2013),Innsbruck,Austria.
Topic: Translational Research and Development of Novel Biomarkers and
Drugs:The Laboratory-Clinical Interface
Supervisers: Prof.Ira-Ida Skvortsova,Prof Wolfgang Hilbe,Prof Lukas A Huber
ABSTRACTS
• Atul Sharma, Nootan Kumar Shukla, Surendra Pal Chaudhary, Ranjit Sahoo, BK
Mohanti, S. V. S. Deo, Sujoy Pal, Sanjay Thulkar, Sunil Kumar, Sushmita Pathy, Peush
Sahni, Sreenivas Vishnubhatla, Sushma Bhatnagar, Nihar Ranjan Dash, Rakesh Kumar,
Vinod Raina, Venkateswaran K Iyer, Seema Mishra “Final results of a phase III
randomized controlled trial comparing modified gemcitabine + oxaliplatin (mGEMOX)
to gemcitabine+ cisplatin in management of unresectable gall bladder cancer
(GBC)”.ASCO Annual Meeting 2016,3-7 June Chicago,USA,Abstract no: 4077(Poster
Presentation )
• S.Chaudhary S,A.Sharma ,T.Tilak ,Bakhshi.S,V.,Raina ,L.Kumar ”A pilot study of
efficacy of lactobacillus CD2 lozenges in preventing high-dose chemotherapy induced
oral mucositis in patients undergoing hematopoietic stem cell

13. transplantation” Multinational Association of Supportive Cancer Care 26-28 June
2014, Miami,Florida,USA.(Final Analysis) (POSTER PRESENTATION)
(Abstract was also selected for MASCC Travel Scholarship Award 2014)
• S.Chaudhary S,A.Sharma ,T.Tilak ,Bakhshi.S,V.,Raina ,L.Kumar ”A pilot study of
efficacy of lactobacillus CD2 lozenges in preventing high-dose chemotherapy induced
oral mucositis in patients undergoing hematopoietic stem cell
transplantation” Multinational Association of Supportive Cancer Care 26-28 June
2014, Miami,Florida,USA.(Final Analysis) (E-POSTER PRESENTATION &
DISCUSSION)
(Abstract was also selected for MASCC Travel Scholarship Award 2014)
• Atul Sharma, Surendra Pal Chaudhary, N K Shukla, B K Mohanti, S V S Deo, Sujoy
Pal, Vinod Raina, Sanjay Thulkar, Sreenivas Vishnubhatla, Rakesh Kumar,
V K Iyer “A randomized controlled trial comparing modified gemcitabine plus
oxaliplatin (mGEMOX) to gemcitabine plus cisplatin in the management of unresectable
gall bladder cancer.ASCO Annual meeting 2014,Abstract no:TPS 4152.May 30th
-3rd
June 2014,Chicago ,Illinois,USA.(POSTER PRESENTATION)
• S Bharti, S Prakash, S P Chaudhary and A Sharma, "Expression of matrix
metalloproteinase’s, proinflammatory cytokines and nitric oxides in head and neck cancer
patients receiving the radiation and chemotherapy" SFRR-INDIA-14
Conference, abstract has been accepted for poster presentation
for SFRR(Society of Free Radical Research)-INDIA-Young Investigator (YA)
Award, held at Treasure Island Resort, Lonavala, Maharashtra INDIA
during January 27-30, 2014
• Sharma A, Rath GK, Chaudhary SP, Thakar A, Mohanti BK, Bahadur S, A randomized
double-blind phase III study of efficacy of lactobacillus CD2 lozenges in preventing
radiation- and chemotherapy-induced oral mucositis in head and neck cancer
patients” Indian Cancer Congress 21st
to 24th
Nov 2013,New Delhi,INDIA
(Landmark Paper Session)
• Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK,
Thulkar S, Garg P, and Chaudhary SP . Best supportive care versus chemotherapy for
unresectable gall bladder cancer: a randomized controlled study” ” Indian Cancer
Congress 21st
to 24th
Nov 2013,New Delhi,INDIA (Landmark Paper Session)
• Sharma A,Chaudhary SP,Sreenivas V,Prakash S,Raina V,Shukla NK “ A phase II / III,
randomized, double-blind, placebo controlled study to investigate the efficacy of a
probiotic VSL#3®
, on Chemotherapy-induced diarrhoea in cancer patients receiving
fluropyrimidines and or irinotecan (Interim analysis)” Abstract no 1319 ECCO-ESMO-
ESTRO 27th
-1st
October 2013,Amsterdam,Netherland.(POSTER PRESENTATION)

14. • TVSVGK Tilak, Lalit Kumar, Atul Sharma, Sameer Bakhshi, Ranjit Kumar Sahoo, Smita
Kayal, Surendra Chaudhary, Vinod Raina”Clinical Features and Outcome of Relapsed
Refractory Aggressive Peripheral T-cell Lymphoma- A Ten-Year Study From A Single
Institute In India”ECCO-ESMO-ESTRO 27th
-1st
October
2013,Amsterdam,Netherland.(POSTER PRESENTATION)
• Atul Sharma, Surendra Pal Chaudhary, N K Shukla, B K Mohanti, S V S Deo, Sujoy
Pal, Vinod Raina, Sanjay Thulkar, Sreenivas Vishnubhatla, Rakesh Kumar,
V K Iyer “A randomized controlled trial comparing modified gemcitabine plus
oxaliplatin (mGEMOX) to gemcitabine plus cisplatin in the management of unresectable
gall bladder cancer.ASCO Annual meeting 2013,Abstract no:TPS 4162.May 31st
-4th
June 2013,Chicago ,Illinois,USA.(POSTER PRESENTATION)
• A.Sharma Tilak Tvsvgk,V.Raina ,L.Kumar,Sameer Bakhshi,Surendra Pal Chaudhary
and Ranjit Kumar Sahoo ”A pilot study of efficacy of lactobacillus cd2 lozenges in
preventing high-dose chemotherapy induced oral mucositis in patients undergoing
hematopoietic stem cell transplantation. Blood (ASH Annual Meeting Abstract) 2012
120:Abstract 4500 (Interim Analysis)
• Sharma A, Mohanti BK, Thakar A, Chaudhary SP, Bhaskar.S, Bahadur S, Sharma
A,Concomitant chemoradiation using weekly cisplatin for advanced squamous cell
carcinoma of head and neck: Experience from tertiary cancer center in India.ASCO
Annual meeting 2011 ,Abstract no:5548) June3-7,2011,Chicago,Illinois,USA.(POSTER
PRESENTATION)
• Sharma A, Rath GK, Chaudhary SP, Thakar A, Mohanti BK, Bahadur S, A randomized
double-blind phase III study of efficacy of lactobacillus CD2 lozenges in preventing
radiation- and chemotherapy-induced oral mucositis in head and neck cancer
patients.MASCC (Multinational Association of supportive cancer care,) Abstract no:
A-327-0019-00278, June 23-25,2011,Athens,GREECE. (ORAL PRESENTATION)
• Sharma A, Rath GK, Chaudhary SP, Thakar A, Mohanti BK, Bahadur S, Sahu AR,
Johar A, and Dwary A. A randomized double-blind phase III study of efficacy of
lactobacillus CD2 lozenges in preventing radiation- and chemotherapy-induced oral
mucositis in head and neck cancer patients: Interim analysis, ASCO Annual meeting
2009,Orlando,Florida,USA. J Clin Oncology( Meeting Abstracts) 2009 27: 6008.
(ORAL PRESENTATION)
RESEARCH PUBLICATIONS :
• Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK,
Thulkar S, Garg P, and Chaudhary SP . Best supportive care versus chemotherapy for
unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical
Oncology . 2010: 20; 28(30):4581-6.PMID:20855823

15. • Sharma A, Rath GK, Chaudhary SP, Thakar A, Mohanti BK, Bahadur S, A randomized
double-blind phase III study of efficacy of lactobacillus CD2 lozenges in preventing
radiation- and chemotherapy-induced oral mucositis in head and neck cancer
patients. European Journal of cancer.doi:10.1016/j.ejca.2011.06.010.PMID:21741230
• Biswas B, SharmaA, Makharia GK, Thulkar S, Arava S,Bahl A,Chaudhary
S.Immunoproliferative small intestinal disease: report of 6 cases from AIIMS, New
Delhi. Tropical Gastroenterology. 2014;35(4) :269-272.
• Sharma A, Tilak TVSVGK, Bakhshi S, Raina V, Kumar L, Chaudhary SP, Sahoo R,
Gupta , Thulkar, SLactobacillus brevis CD2 lozenges prevent oral mucositis in patients
undergoing high dose chemotherapy followed by haematopoietic stem cell
transplantation.(Manuscript Submitted-under review)
PRACTICE CHANGING STUDIES FROM OUR CENTER :
• Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK,
Thulkar S, Garg P, and Chaudhary SP . Best supportive care versus chemotherapy for
unresectable gall bladder cancer: a randomized controlled study. Journal of Clinical
Oncology. 2010: 20; 28(30):4581-6.PMID:20855823
• Sharma A, Rath GK, Chaudhary SP, Thakar A, Mohanti BK, Bahadur S, A randomized
double-blind phase III study of efficacy of lactobacillus CD2 lozenges in preventing
radiation- and chemotherapy-induced oral mucositis in head and neck cancer
patients. European Journal of cancer.doi:10.1016/j.ejca.2011.06.010.PMID:21741230
 (Two of the above mentioned studies in which I was the Co-Investigator and Co-
Author were recognized at various National and International platform and are now
the standard of care in treatment of 1
unresectable and metastatic gall bladder cancer
and 2
prevention of mucositis in the patient who are undergoing CTRT in HNSCC
which has now been approved for marketing by NDAC DGCI-Drug Control General
of India.)
REFRENCES :
• Dr Atul Sharma, MD, DM
Professor (Medical Oncology),
Dr.BRA.Institute Rotary Cancer Hospital,
All India Institute of Medical Sciences,
New Delhi, 110029, INDIA

16. Phone & Fax: +91-11-26589490
atul1@hotmail.com
• Prof. S.V.S.Deo, MS,FRCS
Professor (Surgical Oncology)
Dr.BRA.Institute Rotary Cancer hospital
All India Institute of Medical Sciences,
New Delhi, 110029, INDIA
svsdeo@yahoo.co.in
• Dr Shyam Prakash,PhD
Assistant Professor (Lab Medicine)
All India Institute of Medical Sciences
New Delhi 110029,INDIA
prakashaiims@gmail.com
• Dr. Rakesh Verma, Ph.D (Medical Oncology)
Yale University
New Haven CT, 06510, USA
Phone:+12074205923
rakesh.9.84@gmail.com , rakesh.verma@yale.edu